Full-Time
Translational Biologist
Autophagy
Retro Biosciences
51-200 employees
Develops therapeutics to extend healthy lifespan
Compensation Overview
$130k - $160k/yr
Mid, Senior
San Carlos, CA, USA
- Ph.D. in Biology, Pharmacology, or a related discipline with a focus on translational research with minimum of 3-5 years of relevant experience in translational research within academic or industry settings.
- Proficiency in independently designing and conducting laboratory experiments, with expertise in data analysis tools and methodologies.
- Experience with CRO management and tech transfer.
- Proven ability to effectively convey research findings, verbally and in writing.
- A collaborative mindset and experience working within interdisciplinary teams.
- A track record of tackling complex scientific questions and contributing to innovative solutions in drug development.
- Strong leadership and problem-solving skills.
- A proactive, problem-solving approach and the ability to identify risks early and implement solutions effectively.
- Lead and execute research projects that connect preclinical findings with clinical outcomes.
- Develop and conduct in vitro experiments, and design in vivo studies to investigate disease pathways and assess the pharmacological profiles of potential therapeutics.
- Support biofluid-based (plasma, CSF) biomarker readouts that inform mechanism of action or patient response models of Alzheimer’s Disease.
- Implement biomarker analysis in clinical laboratory studies under regulatory guidelines.
- Develop PD biomarkers(i.e. qPCR, FACS, ELISA, MSD, Luminex, Simoa, enzyme assays).
- Lead tech transfer to and manage work with CROs.
- Collaborate with teams in molecular biology, clinical research, and regulatory affairs to ensure cohesive progression of drug candidates through the development pipeline.
- Contribute to the preparation of regulatory submissions by providing scientific data and insights to support regulatory submissions.
- Analyze preclinical biomarkers in models of neurodegenerative diseases.
- Familiarity with regulatory guidelines pertinent to drug development and translational research.
- Experience in neurodegenerative diseases or Alzheimer's Disease clinical trials.
Retro Biosciences focuses on extending healthy human lifespan by ten years through the development of therapeutics that target the cellular mechanisms of aging. The company addresses the root causes of age-related diseases, which are responsible for a significant portion of healthcare costs in the U.S. Retro Biosciences has three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of development. They utilize advanced technologies like single-cell multi-omics and computational biology to support their research. With $180 million in funding, Retro Biosciences aims to achieve proofs of concept for its treatments, positioning itself to make significant contributions to age-related disease prevention.
Company Size
51-200
Company Stage
Early VC
Total Funding
$180M
Headquarters
Redwood City, California
Founded
2021
Simplify's Take
What believers are saying
- Retro Biosciences secured $1 billion in funding to support its longevity mission.
- Partnerships with MCRI and Multiply Labs enhance therapeutic development and manufacturing capabilities.
- Growing interest in personalized medicine aligns with Retro's focus on autologous cell therapies.
What critics are saying
- Intensifying competition in the longevity biotech sector may impact funding and partnerships.
- Public and regulatory scrutiny of anti-aging therapies could lead to stricter regulations.
- Reliance on large funding rounds poses financial risks if market conditions change.
What makes Retro Biosciences unique
- Retro Biosciences focuses on cellular reprogramming, autophagy, and plasma-inspired therapeutics.
- The company aims to extend healthy human lifespan by ten years.
- Retro Biosciences employs advanced technologies like single-cell multi-omics and computational biology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 4%MCRI, a flagship member of the Melbourne Biomedical Precinct and the Melbourne arm of the international research consortium, the Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW, has today announced a significant research and commercial licensing agreement with Retro Biosciences.
By integrating MCRI's cutting-edge discoveries with its proprietary platforms, Retro Biosciences aims to develop novel, autologous blood stem cell therapies that could eliminate the fatal risks associated with donor mismatches and immunological rejection.
Retro Biosciences, a longevity startup, has partnered with the Murdoch Children’s Research Institute in Australia to develop personalized blood disorder therapies. The company, backed by Sam Altman, is seeking $1 billion in funding.
Sam Altman is backing Retro Biosciences with a new funding round of $1 billion to extend human lifespan.
Retro Biosciences, a biotech company backed by OpenAI CEO Sam Altman, plans to raise $1 billion to fund its project aimed at extending human lifespan by 10 years. Altman initially provided $180 million in seed funding and will contribute more in the Series A round.